Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
13,303 total articles
Douglas R. Timmerman, President of Dealer Financial Services at Ally Financial Inc. (NYSE: ALLY), sold 39,675 shares of company stock on April 17, 2026, raising $1,792,175 at a weighted average price of $45.1714 per share under a Rule 10b5-1 plan adopted December 3, 2025. After the sale he retains 477,627 shares. Ally reported first-quarter 2026 EP…
Diane W. Strong-Treister, a director at City Holding Co. (CHCO), bought 119 shares on April 20, 2026, spending $15,036 under a Rule 10b5-1 trading plan. After the trade she directly owns 3,987 shares and indirectly holds 1,900 shares in a revocable trust. Separately, the company’s board has approved a repurchase program for up to 1,000,000 common s…
Josh Silverman, Executive Chair of Etsy Inc., sold 54,665 shares of the company’s common stock on April 16 and April 20, 2026, for roughly $3.38 million under a Rule 10b5-1 trading plan. The transactions followed option exercises of the same number of shares at an exercise price of $10.62 per share. The stock has shown strong momentum in recent per…
Fastly Inc. CEO Charles Lacey Compton III sold $720,312 of Class A common stock across a series of trades on April 16-17, 2026. The transactions, carried out at prices between $23.69 and $25.40 per share, included a tax-related disposition tied to the vesting of restricted stock units and several sales under a Rule 10b5-1 plan. The stock has climbe…
Micah R. Conrad, Executive Vice President and Chief Operating Officer at OneMain Holdings, Inc. (NYSE: OMF), sold common stock worth $300,000 on April 17, 2026. The transaction, executed under a Rule 10b5-1 trading plan established on November 18, 2025, consisted of 5,000 shares at $60.00 per share. The company recently reported fourth-quarter 2025…
Lazarus Energy Holdings, LLC acquired 72,500 shares of Blue Dolphin Energy Co. (NASDAQ: BDCO) between April 16 and April 20, 2026, investing $222,675 at prices ranging from $2.80 to $3.25. The purchases raise Lazarus Energy's direct stake to 8,547,500 shares. Blue Dolphin's CEO and company leader, Jonathan Carroll, also holds 4,125,000 shares direc…
Vernon Rogers, Executive Vice President of Sales & Marketing at Aehr Test Systems (NASDAQ: AEHR), sold 2,431 shares on April 20, 2026, for $90.00 per share, receiving $218,790. After the sale he directly holds 159,202 shares, including shares subject to unvested restricted stock units. The company also reported a record $41 million production order…
John Steven Emerson, a 10% stakeholder in Coda Octopus Group, Inc. (NASDAQ: CODA), sold approximately $1.29 million worth of common stock on March 11, 2026, via a combination of direct sales and a gift. The transactions, executed through several trusts and retirement accounts, involved 86,254 shares sold at prices between $14.45 and $14.99 and a se…
Argan Inc. CEO David Hibbert Watson sold 19,310 shares of company stock on April 17, 2026, generating $11,626,744 at an average price of $602.11 per share. The sale followed the vesting of multiple restricted stock units across April 16-17, 2026. AGX shares have risen sharply over the past year and trade close to their 52-week peak, while a recent …
Julie Gruber, Chief Legal & Compliance Officer at Gap Inc. (GAP), sold 5,302 shares of common stock on April 17, 2026 under a Rule 10b5-1 trading plan and simultaneously exercised 5,302 non-qualified stock options granted in 2022. The sales and exercises leave Gruber with a direct holding of 58,414.4577 shares and outstanding options to purchase 42…
Mark N. Rogers, Executive Vice President and General Counsel of Amkor Technology (AMKR), sold 5,000 shares of common stock on April 16, 2026, for $59.43 per share, generating $297,150. The sale coincided with the exercise of 5,000 employee stock options at $7.40 per share on the same day. Rogers adopted a Rule 10b5-1 trading plan on August 1, 2025,…
Aehr Test Systems director Rhea J. Posedel sold 7,500 shares on April 20, 2026, for $88.09 each, totaling $660,675, according to a Form 4 filing. The company meanwhile reported a record $41 million production order for package-level burn-in of custom AI processor ASICs, posted mixed Q3 2026 results, and recorded strong bookings that lifted backlog …
Dolphin Entertainment Chief Executive William O’Dowd IV acquired 3,200 shares on April 20, 2026, paying a weighted average of $1.524 per share for a total of $4,876. The transaction raises his direct and indirect holdings in the company amid 2025 revenue growth and a cautious market reaction to recent earnings.
CareDx Chief Executive John Walter Hanna Jr. sold 10,282 shares of company stock on April 16, 2026, for a total of $217,155 at $21.12 per share under a Rule 10b5-1 trading plan. The transaction occurred as shares had risen sharply in recent periods. The company recently reported strong fourth-quarter results, provided 2026 revenue guidance above co…
United Therapeutics Chairperson and CEO Martine A. Rothblatt sold 9,500 shares under a pre-arranged 10b5-1 plan on April 17, 2026, generating roughly $5.57 million. The transaction followed an option exercise of 9,500 shares at $146.03 per share, and occurred while the stock traded close to its 52-week high of $607.89 after a 107% gain over the pas…
Hims & Hers Health, Inc. Chief Financial Officer Okupe Oluyemi sold 54,927 shares of Class A common stock across two transactions in mid-April, generating about $1.46 million. The trades were executed under a Rule 10b5-1 plan adopted on May 21, 2025. Mr. Oluyemi also exercised options for 6,184 shares and retains significant direct, indirect an…
Cynthia H. Davis, a director at Citizens, Inc. (NASDAQ:CIA), reported several purchases of the company’s Class A shares across early 2026, including an indirect acquisition of 100 shares on March 25, 2026. Separately, the company’s board approved higher compensation for Chief Executive Officer Jon Stenberg effective April 1, 2026. An InvestingPro n…
Morgan Stanley Chief Legal/Admin Officer Eric F. Grossman sold 11,118 shares of the company's common stock on April 20, 2026, totaling $2,120,758. The sale occurred as the stock traded near its 52-week high and after a year of substantial gains. The bank also reported stronger-than-expected first-quarter results and drew renewed analyst attention, …
Andrew Dakos, President and CEO of Total Return Securities Fund (NASDAQ:SWZ), purchased $68,314 worth of the fund’s common stock across transactions on April 16 and April 17, 2026. The buys, executed at prices between $6.04 and $6.09 per share, come while the stock is trading close to its 52-week low and after a recent Form 4 amendment correcting i…
Jorge Andres Cedron, Chief Legal Officer of Orthofix Medical Inc. (NASDAQ:OFIX), sold 3,743 shares on April 16, 2026 for $47,985 at $12.82 per share to meet tax withholding obligations related to restricted stock unit settlement. The sale was carried out under a pre-authorized sell-to-cover program approved by the Compensation and Talent Developmen…
Cognition Therapeutics President and CEO Lisa Ricciardi bought $10,092 of company stock on April 16, 2026, increasing her direct holdings to 1,715,851 shares. The transaction coincides with the company reporting a reduced net loss for 2025 and plans to engage the FDA on a registrational pathway for zervimesine following positive Phase 2 SHIMMER res…
John Brendan Doyle, chief financial officer of Cognition Therapeutics Inc. (NASDAQ: CGTX), purchased 10,000 shares of the company on April 16, 2026, at $1.13 per share. The transaction increased his direct holdings to 627,509 shares. The buy coincides with strong recent stock performance and company updates showing narrower losses and a plan to pur…
Anthony Caggiano, Chief Medical Officer of Cognition Therapeutics Inc. (NASDAQ: CGTX), bought 10,000 shares on April 16, 2026, paying $1.11 per share for a total of $11,100. The transaction leaves him with 874,906 shares on a direct basis. The purchase comes amid notable share-price momentum and follows the company’s 2025 results, which showed a re…
Exzeo Group CEO Paresh Patel purchased 2,000 shares of company stock on April 17, 2026, for $33,880. The deal increases his direct holdings to 1,618,013 shares. The company reported fourth-quarter and full-year 2025 results in line with analyst expectations, with diluted EPS of $0.25 and quarterly revenue of $53.32 million. Exzeo’s shares rose afte…
Belite Bio's Chief Scientific Officer, Nathan L. Mata, sold 1,000 American depositary shares on April 16, 2026, totaling roughly $160,380. The transactions were carried out under a Rule 10b5-1 trading plan. The company is progressing toward a New Drug Application submission for tinlarebant following positive Phase 3 DRAGON results, prompting severa…
